Home » Stocks » ADPT

Adaptive Biotechnologies Corporation (ADPT)

Stock Price: $67.74 USD 0.73 (1.09%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $66.95 -0.79 (-1.17%) Jan 22, 7:57 PM
Market Cap 9.26B
Revenue (ttm) 92.41M
Net Income (ttm) -122.27M
Shares Out 134.37M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $67.74
Previous Close $67.01
Change ($) 0.73
Change (%) 1.09%
Day's Open 66.71
Day's Range 65.67 - 68.16
Day's Volume 293,229
52-Week Range 16.96 - 68.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

Multi-year, pan-portfolio deal extends Adaptive's proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology

GuruFocus - 2 weeks ago

During GuruFocus' annual model portfolio rebalance for 2021, the new stocks added to the Most Weighted Model Portfolio were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), AerCap Holdings NV (NY...

Other stocks mentioned: AER, BABA, DIS, PCG, TRN
GlobeNewsWire - 3 weeks ago

SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...

Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to Adaptive Biotechnologies (ADPT) stock based on the movements in the options market lately.

GuruFocus - 1 month ago

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarte...

Other stocks mentioned: BBIO, BSX, CNC, TMO
GlobeNewsWire - 1 month ago

MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment MRD assessment with cl...

GlobeNewsWire - 2 months ago

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive imm...

GuruFocus - 2 months ago

Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global, disclosed this week that his firm's top sells during the third quarter were in Amazon.com Inc. (NASDAQ:AMZN), Comcas...

Other stocks mentioned: AMZN, CMCSA, JD, UBER
The Motley Fool - 2 months ago

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

Other stocks mentioned: BLUE, BPMC, NVAX, RHHBY
GeekWire - 2 months ago

Adaptive Biotechnologies says it's proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a s...

GlobeNewsWire - 2 months ago

– Findings support upcoming launch of T-Detect ™ COVID , first T- cell test for novel coronavirus – Data support mounting evidence that measuring T- cell s is necessary to fully characteriz e ...

Seeking Alpha - 2 months ago

Adaptive Biotechnologies' (ADPT) CEO Chad Robins on Q3 2020 Results - Earnings Call Transcript

GeekWire - 2 months ago

Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.

Other stocks mentioned: GSK
Zacks Investment Research - 2 months ago

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 3.57% and 12.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...

Benzinga - 2 months ago

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 145.45% over the past year t...

GlobeNewsWire - 2 months ago

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive imm...

GlobeNewsWire - 2 months ago

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...

Zacks Investment Research - 2 months ago

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNBC Television - 3 months ago

Adaptive Biotech CEO says it's working to develop the best antibody treatment for Covid-19

Adaptive biotechnologies CEO Chad Robins says the company is working night and day to develop an effective antibody Covid-19 treatment. He says the company won't be first to provide antibody t...

GlobeNewsWire - 3 months ago

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immu...

GlobeNewsWire - 4 months ago

SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive ...

Seeking Alpha - 5 months ago

Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium

CNBC Television - 5 months ago

Adaptive Biotechnologies CEO on Covid-19 research efforts, Russia vaccine claims

Chad Robins, Adaptive Biotechnologies co-founder and CEO, joins "Squawk Box" to discuss the company's research efforts to develop a Covid-19 vaccine as well as Russian President Vladimir Putin...

Seeking Alpha - 5 months ago

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2020 Results - Earnings Call Transcript

GeekWire - 5 months ago

Adaptive Biotechnologies’ revenue fell 5% to $21 million in the second quarter, and its net loss more than doubled to $33.

Zacks Investment Research - 5 months ago

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.33% and 3.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...

GlobeNewsWire - 5 months ago

SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate t...

GlobeNewsWire - 5 months ago

SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...

GlobeNewsWire - 5 months ago

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

GlobeNewsWire - 5 months ago

Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials

The Motley Fool - 5 months ago

Does this unusual biotech stock have what it takes to deliver market-beating gains?

GlobeNewsWire - 5 months ago

Current tests are highly inaccurate, resulting in lengthy diagnostic journey Current tests are highly inaccurate, resulting in lengthy diagnostic journey

GeekWire - 5 months ago

Topping-off ceremonies, in which workers place the last piece of structural steel for new building, have become run-of-the-mill over the past decade in Seattle’s South Lake Union neighborhood.

Zacks Investment Research - 6 months ago

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 6 months ago

SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...

GeekWire - 6 months ago

Adaptive Biotechnologies announced Tuesday that it will sell 8 million shares of its common stock to help accelerate the company’s work.

GlobeNewsWire - 6 months ago

SEATTLE, July 14, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...

The Motley Fool - 6 months ago

Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.

GlobeNewsWire - 6 months ago

SEATTLE, July 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive i...

The Motley Fool - 6 months ago

Why Adaptive Biotechnologies and Smartsheet will be mega-cap stocks in the future.

Other stocks mentioned: SMAR
Zacks Investment Research - 7 months ago

Adaptive Biotechnologies (ADPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GeekWire - 7 months ago

Seattle-based Adaptive Biotechnologies and Microsoft have launched an open-access database called ImmuneCODE to catalog the many ways in which our immune systems fight off a coronavirus infect...

Other stocks mentioned: MSFT
GlobeNewsWire - 7 months ago

SEATTLE, June 08, 2020 (GLOBE NEWSWIRE) -- This release was previously disseminated on May 27, 2020 at 16:03 ET. The date and time details for the conferences have been updated. The complete...

GlobeNewsWire - 7 months ago

SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive im...

Zacks Investment Research - 8 months ago

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

Other stocks mentioned: AMGN, CYDY, GILD, REGN
GeekWire - 8 months ago

In the realm of diagnostic tests for COVID-19, there are two main approaches: PCR tests, which detect the presence of the live virus; and serology tests, which detect antibodies that indicate ...

Other stocks mentioned: MSFT
The Motley Fool - 8 months ago

Revenue skyrocketed in the first quarter. But so did Adaptive's spending.

Seeking Alpha - 8 months ago

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q1 2020 Results - Earnings Call Transcript

GeekWire - 8 months ago

Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter reve...

GlobeNewsWire - 8 months ago

SEATTLE, May 12, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate th...

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline o... [Read more...]

Industry
Biotechnology
IPO Date
Jun 27, 2019
CEO
Chad Robins
Employees
453
Stock Exchange
NASDAQ
Ticker Symbol
ADPT
Full Company Profile

Financial Performance

In 2019, ADPT's revenue was $85.07 million, an increase of 52.83% compared to the previous year's $55.66 million. Losses were -$68.61 million, 47.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 62.60, which is a decrease of -7.59% from the latest price.

Price Target
$62.60
(-7.59% downside)
Analyst Consensus: Buy